{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T15:44:26Z","timestamp":1778341466016,"version":"3.51.4"},"reference-count":79,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background\/Objectives: The field of nephrology is increasingly embracing advanced treatments and clinical trials that focus on inhibiting specific components of the complement cascade, a key driver in complement-mediated kidney diseases. Materials and Methods: This review aims to summarize innovative therapies targeting various pathways, including the inhibition of the terminal part of the complement pathway (mainly C5), the alternative pathway (factor B inhibitors), and the lectin pathway (MASP inhibitors. C5 inhibitors play a critical role in preventing the formation of the membrane attack complex (MAC), offering effective solutions for conditions like atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). Meanwhile, avacopan, a C5a receptor antagonist, addresses ANCA-associated vasculitis (AAV) by mitigating inflammation and enabling reduced reliance on corticosteroids. Similarly, narsoplimab, which inhibits MASP-2, targets the lectin pathway implicated in conditions such as aHUS. Iptacopan, a factor B inhibitor, focuses on the alternative pathway and demonstrates efficacy in managing C3 glomerulopathy (C3G). Results: A systematic review of complement-targeted therapies was conducted, analysing studies from 2013 to 2023 that address unmet medical needs in primary and secondary glomerular diseases. Conclusions: Our systematic review of complement-targeted therapies shows that these tailored and innovative treatments may specifically address unmet medical needs in primary and secondary glomerular diseases.<\/jats:p>","DOI":"10.3390\/medicina61071205","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T05:28:28Z","timestamp":1751347708000},"page":"1205","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting the Roots of Kidney Disease: Systematic Review of the Therapies Targeting the Complement System"],"prefix":"10.3390","volume":"61","author":[{"given":"Maja","family":"Roman","sequence":"first","affiliation":[{"name":"Department of Nephrology, Hypertension, Transplantation and Internal Medicine, Central University Hospital, Medical University of Lodz, Pomorska 251, 92-213 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0823-5440","authenticated-orcid":false,"given":"Micha\u0142","family":"Nowicki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension, Transplantation and Internal Medicine, Central University Hospital, Medical University of Lodz, Pomorska 251, 92-213 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: A key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.smim.2013.04.001","article-title":"Complement inhibition: A promising concept for cancer treatment","volume":"25","author":"Pio","year":"2013","journal-title":"Semin. Immunol."},{"key":"ref_3","unstructured":"Biopharma PEG (2025, January 09). Complement Inhibitors as Therapeutic Agents. Available online: https:\/\/www.biochempeg.com\/article\/281.html."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Dudler, T., Yaseen, S., and Cummings, W.J. (2023). Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway\u2013mediated disorders. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1297352"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1182\/blood-2023-177730","article-title":"Alternative pathway Masp-3 inhibitor OMS906 effectively and potently inhibits complement-mediated hemolysis in preclinical models mechanistically similar to paroxysmal nocturnal hemoglobinuria","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00277-022-04903-x","article-title":"Inhibition of C3 with Pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria","volume":"101","author":"Wong","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","article-title":"Clinical safety and efficacy of Pegcetacoplan in a phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases","volume":"8","author":"Dixon","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_8","unstructured":"National Center for Biotechnology Information (2025, January 23). PubChem Compound Summary for CID 118126201, Amy-101, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Amy-101."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1159\/000527167","article-title":"Clinical outcomes of patients with C3G or IC-MPGN treated with the factor D inhibitor Danicopan: Final results from two phase 2 studies","volume":"53","author":"Nester","year":"2023","journal-title":"Am. J. Nephrol."},{"key":"ref_10","first-page":"329","article-title":"FDA approves first complement factor D inhibitor","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e240103","DOI":"10.57264\/cer-2024-0103","article-title":"Ravulizumab in adults and children with atypical hemolytic uremic syndrome: A plain language summary of three studies","volume":"13","author":"Nowicki","year":"2024","journal-title":"J. Comp. Eff. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/ajh.27413","article-title":"Phase 3 randomized COMMODORE 1 trial: Crovalimab versus Eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria","volume":"99","author":"Scheinberg","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.23876\/j.krcp.21.248","article-title":"Application of C5 inhibitors in glomerular diseases in 2021","volume":"41","author":"Werion","year":"2022","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_14","unstructured":"U.S. Food and Drug Administration (2025, January 23). FDA Approves First Interchangeable Biosimilar for Two Rare Diseases. 28 July 2021, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-interchangeable-biosimilar-two-rare-diseases."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2215\/CJN.0000000000000384","article-title":"Phase 2 trial of Cemdisiran in adult patients with IgA nephropathy: A randomized controlled trial","volume":"19","author":"Barratt","year":"2024","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101210","DOI":"10.1016\/j.blre.2024.101210","article-title":"Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"66","author":"Xu","year":"2024","journal-title":"Blood Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1681\/ASN.0000000526","article-title":"Safety and efficacy of Avacopan in patients with C3 glomerulopathy","volume":"36","author":"Bomback","year":"2025","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_18","first-page":"132","article-title":"Protection of host cells by complement regulators","volume":"16","author":"Schmidt","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_19","unstructured":"Apellis Pharmaceuticals (2025, January 23). Apellis Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naive Patients with Geographic Atrophy. 14 November 2018. Available online: https:\/\/investors.apellis.com\/news-releases\/news-release-details\/apellis-dosed-first-patient-phase-3-study-apl-2-treatment-naive."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00467-018-4091-3","article-title":"Eculizumab in atypical hemolytic uremic syndrome: Strategies toward restrictive use","volume":"34","author":"Wijnsma","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"ref_21","unstructured":"National Library of Medicine (2025, January 09). Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01221181."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.kint.2020.10.046","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"100","author":"Ariceta","year":"2021","journal-title":"Kidney Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.it.2017.03.003","article-title":"Complement C3-targeted therapy: Replacing long-held assertions with evidence-based discovery","volume":"38","author":"Mastellos","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_25","unstructured":"PRISMA Group (2024). Transparent Reporting of Systematic Reviews and Meta-Analyses. PRISMA Statement, PRISMA Group."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1016\/j.ekir.2024.06.020","article-title":"Global aHUS Registry Analysis of Patients Switching to Ravulizumab from Eculizumab","volume":"9","author":"Schaefer","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"ref_27","unstructured":"National Library of Medicine (2025, January 09). A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Participants with Atypical Hemolytic Uremic Syndrome (aHUS) (COMMUTE-p), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04958265."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1681\/ASN.20223311S1189a","article-title":"Long-term outcomes in eculizumab-treated patients enrolled in the global AHUS registry","volume":"33","author":"Greenbaum","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S460","DOI":"10.1016\/j.ekir.2022.04.074","article-title":"Two phase III trials evaluating crovalimab in patients with atypical haemolytic uraemic syndrome (aHUS): COMMUTE-a and COMMUTE-p","volume":"7","author":"Sheerin","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"gfae069-1195-1222","DOI":"10.1093\/ndt\/gfae069.1195","article-title":"Crovalimab: Patient preferences and ongoing phase III COMMUTE trials in acute haemolytic uraemic syndrome (aHUS)","volume":"39","author":"Gentile","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5582\/irdr.2014.01001","article-title":"Current treatment of atypical hemolytic uremic syndrome","volume":"3","author":"Kaplan","year":"2014","journal-title":"Intractable Rare Dis. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1016\/j.ekir.2023.09.017","article-title":"Efficacy and safety of Iptacopan in patients with C3 glomerulopathy","volume":"8","author":"Wong","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ekir.2022.07.004","article-title":"Alternative complement pathway inhibition with Iptacopan for the treatment of C3 glomerulopathy: Study design of the APPEAR-C3G trial","volume":"7","author":"Bomback","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_34","unstructured":"Fierce Pharma (2025, January 09). Amyndas\u2019 Lead Candidate AMY-101 Receives Orphan Drug Status from the FDA and the EMA for the Treatment of C3 Glomerulopathy. Available online: https:\/\/www.fiercepharma.com\/pharma\/amyndas-lead-candidate-amy-101-receives-orphan-drug-status-from-fda-and-ema-for-treatment-c3."},{"key":"ref_35","unstructured":"Novartis (2025, January 09). Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Highly Statistically Significant Proteinuria Reduction in Patients with IgA Nephropathy (IgAN). Available online: https:\/\/www.novartis.com\/news\/media-releases\/novartis-investigational-iptacopan-phase-iii-study-demonstrates-clinically-meaningful-and-highly-statistically-significant-proteinuria-reduction-patients-iga-nephropathy-igan."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/ckj\/sfab294","article-title":"C5a receptor inhibitor avacopan in immunoglobulin A nephropathy\u2014An open-label pilot study","volume":"15","author":"Bruchfeld","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_37","unstructured":"Omeros Corporation (2025, January 09). Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy. Available online: https:\/\/investor.omeros.com\/news-releases\/news-release-details\/omeros-corporation-provides-update-interim-analysis-artemis-igan."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41409-024-02305-3","article-title":"Safety and efficacy of Narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: A real-world experience","volume":"59","author":"Castelli","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_39","first-page":"939","article-title":"Ravulizumab for the treatment of adult patients with atypical hemolytic uremic syndrome: A 52-week interim analysis of a phase 3 study","volume":"5","author":"Rondeau","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s13730-020-00465-x","article-title":"Prophylactic amoxicillin for the prevention of meningococcal infection in infants with atypical hemolytic uremic syndrome under treatment with eculizumab: A report of two cases","volume":"9","author":"Tanaka","year":"2020","journal-title":"CEN Case Rep."},{"key":"ref_41","unstructured":"National Library of Medicine (2025, January 09). Single Patient Expanded Access Treatment Plan for the Investigational Product Narsoplimab, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04247906."},{"key":"ref_42","unstructured":"Wexler, M.S. (2025, June 29). Avacopan May Be Effective Option to Steroids for AAV, Phase 3 Trial Finds. Available online: https:\/\/ancavasculitisnews.com\/news\/avacopan-possible-effective-option-steroids-aav-phase-3-advocate-trial\/."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"100855","DOI":"10.1016\/j.xkme.2024.100855","article-title":"Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials","volume":"6","author":"Dixon","year":"2024","journal-title":"Kidney Med."},{"key":"ref_44","unstructured":"National Library of Medicine (2025, January 09). Evaluate Efficacy and Safety of Iptacopan in Patients with C3 Glomerulopathy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04817618."},{"key":"ref_45","unstructured":"Mayo Clinic (2025, January 09). A Study of Cemdisiran in Adults with Immunoglobulin A Nephropathy (IgAN). Available online: https:\/\/www.mayo.edu\/research\/clinical-trials\/cls-20467506."},{"key":"ref_46","unstructured":"Drugs.com (2025, January 09). Soliris (Eculizumab) FDA Approval History. Available online: https:\/\/www.drugs.com\/history\/soliris.html."},{"key":"ref_47","first-page":"569","article-title":"C3 glomerulopathy: Novel treatment paradigms","volume":"9","author":"Bomback","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_48","unstructured":"European Medicines Agency (2025, January 12). Soliris: EPAR\u2014Product Information, Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/soliris."},{"key":"ref_49","unstructured":"Drugs.com (2025, January 09). Ultomiris (Ravulizumab-cwvz) FDA Approval History. Available online: https:\/\/www.drugs.com\/history\/ultomiris.html."},{"key":"ref_50","unstructured":"European Medicines Agency (2025, January 12). Ultomiris: EPAR\u2014Product Information, Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ultomiris."},{"key":"ref_51","unstructured":"Alexion Pharmaceuticals (2019). ULTOMIRIS (Ravulizumab) Receives Marketing Authorization from the European Commission for the Treatment of Adult and Pediatric Patients with aHUS, Alexion Pharmaceuticals. Available online: https:\/\/media.alexion.com\/news-releases\/news-release-details\/ultomirisr-ravulizumab-receives-marketing-authorization-european."},{"key":"ref_52","unstructured":"Ryan, C., and FDA Approves Crovalimab for Paroxysmal Nocturnal Hemoglobinuria (2025, January 09). OncLive. Available online: https:\/\/www.onclive.com\/view\/fda-approves-crovalimab-for-paroxysmal-nocturnal-hemoglobinuria."},{"key":"ref_53","unstructured":"National Library of Medicine (2025, January 09). Evaluate Long-Term Efficacy and Safety of Investigational Treatment NCT04861259, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04861259."},{"key":"ref_54","unstructured":"Roche (2025, January 09). Positive Phase III Results for Roche\u2019s Gazyva\/Gazyvaro Show Superiority to Standard Therapy Alone in People with Lupus Nephritis. Available online: https:\/\/www.roche.com\/media\/releases\/med-cor-2024-09-26."},{"key":"ref_55","unstructured":"GlobeNewswire (2025, January 09). ChemoCentryx Announces EU Approval of Tavneos\u00ae (Avacopan) for the Treatment of ANCA-Associated Vasculitis. Available online: https:\/\/www.globenewswire.com\/news-release\/2022\/01\/19\/2369344\/19219\/en\/ChemoCentryx-Announces-EU-Approval-of-TAVNEOS-avacopan-for-the-Treatment-of-ANCA-Associated-Vasculitis.html."},{"key":"ref_56","unstructured":"European Medicines Agency (2025, January 12). Tavneos: EPAR\u2014Product Information, Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tavneos."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-024-02054-z","article-title":"Correction: Iptacopan: First approval","volume":"84","author":"Syed","year":"2024","journal-title":"Drugs."},{"key":"ref_58","unstructured":"Novartis (2025, January 09). Novartis oral Fabhalta\u00ae (Iptacopan) Sustained Clinically Meaningful Results at One Year in Phase III C3 Glomerulopathy (C3G) Trial. Available online: https:\/\/www.novartis.com\/news\/media-releases\/novartis-oral-fabhalta-iptacopan-sustained-clinically-meaningful-results-one-year-phase-iii-c3-glomerulopathy-c3g-trial."},{"key":"ref_59","unstructured":"BioSpace (2025, January 25). Omeros Shares Plummet on Phase III Kidney Disease Trial Failure. Available online: https:\/\/www.biospace.com\/omeros-shares-plummet-on-phase-iii-kidney-disease-trial-failure."},{"key":"ref_60","unstructured":"Drugs.com (2025, January 09). Narsoplimab: What Is It and Is It FDA Approved?. Available online: https:\/\/www.drugs.com\/history\/narsoplimab.html."},{"key":"ref_61","unstructured":"Novartis (2025, January 09). Evaluate Long-Term Safety, Tolerability, and Efficacy of Iptacopan in Study Participants with aHUS. Available online: https:\/\/www.novartis.com\/clinicaltrials\/study\/nct05795140."},{"key":"ref_62","unstructured":"Ichgcp.net (2025, January 09). Eculizumab to Cemdisiran Switch in aHUS (DANCE). Available online: https:\/\/ichgcp.net\/clinical-trials-registry\/NCT03999840."},{"key":"ref_63","unstructured":"GlobeNewswire (2025, January 09). Regeneron Pharmaceuticals Announces Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab. Available online: https:\/\/www.globenewswire.com\/news-release\/2024\/12\/08\/2993358\/0\/en\/Novel-Combination-of-Pozelimab-and-Cemdisiran-Poze-Cemdi-Achieved-Greater-Control-of-Intravascular-Hemolysis-in-Patients-with-Paroxysmal-Nocturnal-Hemoglobinuria-Compared-to-Ravuli.html."},{"key":"ref_64","first-page":"95","article-title":"The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target","volume":"313","author":"Risitano","year":"2022","journal-title":"Immunol. Rev."},{"key":"ref_65","unstructured":"European Union Clinical Trials Register (2025, January 09). Clinical Trials Register. Available online: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-004220-11\/PL."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"gfae069-0442-1467","DOI":"10.1093\/ndt\/gfae069.442","article-title":"Pegcetacoplan for post-transplant recurrent C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis in NOBLE: 12-week evolution","volume":"39","author":"Fakhouri","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_67","unstructured":"European Medicines Agency (2025, January 12). Aspaveli: EPAR\u2014Product Information, Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/aspaveli."},{"key":"ref_68","unstructured":"(2025, January 09). FDA Grants Rare Pediatric Disease Designation to Omeros\u2019 MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy. BioSpace. Available online: https:\/\/www.biospace.com\/press-releases\/fda-grants-rare-pediatric-disease-designation-to-omeros-masp-3-inhibitor-zaltenibart-for-treatment-of-c3-glomerulopathy\/."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2023-177921","article-title":"OMS906, a novel alternative pathway MASP-3 inhibitor, normalizes hemoglobin levels and increases clone size in treatment-na\u00efve PNH patients","volume":"142","author":"Karnabeda","year":"2023","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1182\/blood-2024-205866","article-title":"Monotherapy treatment with Zaltenibart (OMS906), an alternative pathway Masp-3 inhibitor, improved key hematologic parameters in patients with PNH with a suboptimal response to Ravulizumab: Interim results from a phase 2 proof-of-concept study","volume":"144","author":"Griffin","year":"2024","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/ejh.14080","article-title":"Long-term effectiveness of eculizumab: Data from the International PNH Registry","volume":"111","author":"Terriou","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/ejh.13783","article-title":"Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies","volume":"109","author":"Kulasekararaj","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Peipert, J.D., Kulasekararaj, A.G., Gaya, A., Langemeijer, S.M.C., Yount, S., Gonzalez-Fernandez, F.A., Gutierrez, E.O., Martens, C., Sparling, A., and Webster, K.A. (2020). Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. PLoS ONE, 15, Available online: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7473546\/.","DOI":"10.1371\/journal.pone.0237497"},{"key":"ref_74","unstructured":"European Medicines Agency (2025, January 22). Piasky: EPAR\u2014Risk Management Plan, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/rmp\/piasky-epar-risk-management-plan_en.pdf."},{"key":"ref_75","unstructured":"(2025, January 22). FabHALTA. Available online: https:\/\/www.fabhalta-hcp.com\/."},{"key":"ref_76","unstructured":"(2025, January 22). Pegcetacoplan: Uses, Side Effects, and Warnings. Drugs.com. Available online: https:\/\/www.drugs.com\/pegcetacoplan.html#side-effects."},{"key":"ref_77","unstructured":"Mayo Clinic (2025, January 22). Avacopan: Description, Uses, and Side Effects. Available online: https:\/\/www.mayoclinic.org\/drugs-supplements\/avacopan-oral-route\/description\/drg-20524765#drug-side-effects."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/jha2.748","article-title":"Results of a phase 1\/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria","volume":"4","author":"Gaya","year":"2023","journal-title":"EJHaem"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1200\/JCO.21.02389","article-title":"Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation\u2013Associated Thrombotic Microangiopathy","volume":"40","author":"Khaled","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/7\/1205\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:02:14Z","timestamp":1760032934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/7\/1205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":79,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["medicina61071205"],"URL":"https:\/\/doi.org\/10.3390\/medicina61071205","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}